Clinical Trial Update: Safety and Efficacy of QAW039 in Sputum Eosinophilia and Persistent Asthma [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluating the safety and efficacy of QAW039 in persistent asthma with sputum eosinophilia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• QAW039

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Asthma | Phase 2 | Status: COMPLETED